ARTISTRY-7: A trial looking at the combination of the drugs Nemvaleukin and Pembrolizumab to treat platinum resistant ovarian cancer

Trial at a glance

Open trial

  • Cancer type: Epithelial – high-grade serous and endometrioid | Epithelial – clear-cell | Epithelial – mucinous
  • Treatment stage: Recurrence
  • Acronym: ARTISTRY-7

ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

You may be able to take part in this trial if you:

  • are 18 years old or over

  • are not pregnant or breastfeeding

  • have a diagnosis of advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

  • have received platinum-based therapy and according to your doctor stopped responding to it (platinum resistance)

  • have received at least one previous treatment for your cancer including a platinum-based treatment and a line of treatment containing bevacizumab (Avastin)

This is not an exhaustive list. If you are interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply. Eligibility will be determined on an individual basis

About the trial

This trial is for those with a diagnosis of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based therapy. It is an open label study, which means that both you and your doctor will know what treatment you are receiving.

The researchers conducting the trial are testing a new treatment called 'nemvaleukin' in combination with another treatment called 'pembrolizumab' or Keytruda® in comparison with chemotherapy. Keytruda is an approved treatment for some types of cancer, but not for platinum-resistant ovarian cancer.

The purpose of the study is to find out how safe it is to use nemvaleukin when combined with pembrolizumab and whether the new combination is more effective than standard chemotherapy. The drugs involved in this clinical trial are

  • Nemvaleukin: is a modified molecule that binds to a protein known as the interleukin-2 (IL-2) receptor and has the potential to stimulate the body’s immune system which may help fight certain types of cancer. It is given intravenously (through the veins) as a drip.
  • Pembrolizumab (Keytruda): a type of immunotherapy. It stimulates the body’s immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells. It is given intravenously (through the veins) as a drip
  • A chemotherapy drug chosen by your doctor (liposomal doxorubicin (Caelyx), paclitaxel, topotecan, or gemcitabine). These are standard chemotherapy drugs that can be used to treat platinum resistant ovarian cancer outside of a clinical trial.

Artistry–7 has 4 different treatment arms and if you take part, you will be randomised (placed into a treatment group by a computer) into one of the groups below:

  1. Nemvaleukin in combination with pembrolizumab
  2. Pembrolizumab only (this group is currently closed and not taking any more patients)
  3. Nemvaleukin only
  4. A chemotherapy drug chosen by your doctor (liposomal doxorubicin (Caelyx), paclitaxel, topotecan, or gemcitabine)

Treatment will continue for as long as the researchers feel it is benefitting you and is tolerable (up to a maximum of 35 nemvaleukin and pembrolizumab cycles.)

This information was last reviewed on 08/02/2024. Please note that the status of clinical trials can change at short notice. You should always check with your clinical team which trials may be suitable for your situation.